Eli Lilly ($LLY) and research partner Incyte ($INCY) released positive new data from the RA-BEACON Phase III trial showing its investigational rheumatoid arthritis pill baricitinib met its primary endpoint of improved ACR 20 response when compared with placebo at week 12. ACR 20 represents at least a 20% improvement across selected measures of disease activity. The data, published in the NEJM, comes as the JAK inhibitor is moving along the FDA regulatory path, which the companies hope will find an approval this year. This follows a series of positive results for the drug in recent years, which analysts believe will hit peak sales of $1.5 billion. Release